Related Experiment Video

Updated: May 20, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections

Karl Weiss1, Robin L Allgren, Sarah Sellers

  • 1Department of Infectious Diseases and Microbiology, Maisonneuve-Rosemont Hospital, Faculty of Medicine, University of Montreal, Quebec, Canada. weisscan@aol.com

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|July 4, 2012
PubMed

Insights

Fidaxomicin, a new antibiotic for Clostridium difficile infections, shows good safety in clinical trials. Its safety profile in adults is comparable to vancomycin, with no significant toxicities noted.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Safety

Background:

  • Clostridium difficile-associated diarrhea (CDAD) is a significant healthcare concern.
  • Fidaxomicin is a novel macrocyclic antibiotic recently approved for CDAD treatment.
  • Evaluating the safety of new antimicrobial agents is crucial for patient care.

Purpose of the Study:

  • To review and summarize the safety data of fidaxomicin.
  • To assess fidaxomicin's safety profile in nonclinical studies and human clinical trials.
  • To compare the safety of fidaxomicin with oral vancomycin in patients with C. difficile infection.

Main Methods:

  • Review of safety data from nonclinical animal studies.
  • Analysis of safety data from Phase 1, 2A, and 3 clinical trials involving healthy volunteers and CDAD patients.
  • Comparative safety analysis against oral vancomycin in Phase 3 trials.

Main Results:

  • Nonclinical studies in dogs showed no significant target-organ toxicities with oral fidaxomicin.
  • A total of 728 adults received oral fidaxomicin in clinical trials.
  • Phase 3 trials indicated fidaxomicin was well tolerated, with a safety profile comparable to oral vancomycin; no significant differences in death or serious adverse events were observed.

Conclusions:

  • Fidaxomicin demonstrates a favorable safety profile in nonclinical and clinical settings.
  • The safety of fidaxomicin is comparable to oral vancomycin for treating C. difficile infections.
  • Postmarketing surveillance will further elucidate the comprehensive safety profile of fidaxomicin.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...